CAMP4 Therapeutics - CAMP Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 163.93%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$3.41
▼ -0.33 (-8.82%)
Get New CAMP4 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CAMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CAMP

Analyst Price Target is $9.00
▲ +163.93% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CAMP4 Therapeutics in the last 3 months. The average price target is $9.00, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 163.93% upside from the last price of $3.41.

This chart shows the closing price for CAMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in CAMP4 Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/4/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/11/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/28/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/2/2025Cantor FitzgeraldSet TargetOverweight$7.00
10/2/2025Cantor FitzgeraldUpgradeStrong-Buy$7.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/18/2025WedbushReiterated RatingOutperform$8.00
9/16/2025JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
9/15/2025Piper SandlerLower TargetOverweight ➝ Overweight$18.00 ➝ $12.00
5/27/2025WedbushInitiated CoverageOutperform$8.00
11/5/2024Leerink PartnrsUpgradeStrong-Buy
11/5/2024Leerink PartnersInitiated CoverageOutperform$17.00
11/5/2024William BlairInitiated CoverageOutperform
11/5/2024Piper SandlerInitiated CoverageOverweight$18.00
11/5/2024JPMorgan Chase & Co.Initiated CoverageOverweight$23.00
10/6/2023Roth MkmLower TargetBuy ➝ Buy$138.00 ➝ $115.00
10/6/2023Craig HallumDowngradeBuy ➝ Hold$11.50
8/29/2023Roth MkmReiterated RatingBuy ➝ Buy$138.00
7/11/2023Craig HallumLower Target$92.00 ➝ $46.00
6/26/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
4/28/2023Craig HallumLower Target$230.00 ➝ $92.00
10/14/2022The Goldman Sachs GroupLower TargetSell$98.90 ➝ $85.10
8/16/2022Craig HallumUpgradeHold ➝ Buy$184.00 ➝ $230.00
3/25/2022Jefferies Financial GroupLower TargetBuy$368.00 ➝ $299.00
12/22/2021Craig HallumDowngradeBuy ➝ Hold$322.00 ➝ $230.00
9/24/2021Craig HallumLower TargetBuy$368.00 ➝ $322.00
6/25/2021Roth CapitalLower TargetBuy$437.00 ➝ $425.50
6/25/2021Craig HallumReiterated RatingBuy$345.00 ➝ $368.00
12/18/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$230.00 ➝ $253.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2025
  • 2 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/6/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
CAMP4 Therapeutics logo
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $3.41
Low: $3.52
High: $4.67

50 Day Range

MA: $2.59
Low: $0.40
High: $4.00

52 Week Range

Now: $3.41
Low: $1.31
High: $12.30

Volume

58,479 shs

Average Volume

83,786 shs

Market Capitalization

$159.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of CAMP4 Therapeutics?

The following Wall Street analysts have issued research reports on CAMP4 Therapeutics in the last year: Cantor Fitzgerald, JPMorgan Chase & Co., Piper Sandler, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for CAMP.

What is the current price target for CAMP4 Therapeutics?

0 Wall Street analysts have set twelve-month price targets for CAMP4 Therapeutics in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 163.9%. Piper Sandler has the highest price target set, predicting CAMP will reach $12.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $7.00 for CAMP4 Therapeutics in the next year.
View the latest price targets for CAMP.

What is the current consensus analyst rating for CAMP4 Therapeutics?

CAMP4 Therapeutics currently has 1 sell rating, 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CAMP.

What other companies compete with CAMP4 Therapeutics?

How do I contact CAMP4 Therapeutics' investor relations team?

CAMP4 Therapeutics' physical mailing address is 15635 Alton Parkway Suite 250, Irvine CA, 92618. The Wireless communications provider's listed phone number is (949) 600-5600 and its investor relations email address is [email protected]. The official website for CAMP4 Therapeutics is www.calamp.com. Learn More about contacing CAMP4 Therapeutics investor relations.